Pediatr. praxi. 2007;8(4):222-226

Actual trends in prevention and treatment of type 1 diabetes mellitus

MUDr. Pavla Mendlová, MUDr. Stanislava Koloušková CSc
Pediatrická klinika 2. LF UK a FN Motol, Praha

Type 1. diabetes mellitus results from an autoimmune destruction of insulin producing pancreatic beta cells. Long interval between the start of the autoimmune process to the real manifestation and the possibility to identify subjects in high risk of the development of the disease based on their genetics, presence of diabetes related autoantibodies and the status of the metabolism of glucose make this disease very attractive target of the prevention on all of its three stages. This article lists in detail important projects of T1DM prevention carried on recently or currently under research and possibilities of replacement or renewal of the insulin self-production, i. e. the causal treatment including the islet transplantations, the stem cell and the gene therapy.

Keywords: T1DM, prediction, prevention, causal therapy

Published: September 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mendlová P, Koloušková S. Actual trends in prevention and treatment of type 1 diabetes mellitus. Pediatr. praxi. 2007;8(4):222-226.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Atkinson M, Eisenbarth G. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 750-754. Go to original source... Go to PubMed...
    2. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005; 25: 74-80. Go to original source... Go to PubMed...
    3. Bingley PJ, Williams AJK, Bonifacio E. Prediction of IDDM in the general population. Strategies based on combination of autoantibody markers. Diabetes 1997; 46: 1701-1710. Go to original source... Go to PubMed...
    4. Bingley PJ, Williams AJK, Gale EAM. Optimized autoantibody-based risk assessment in family members. Diabetes Care 1999; 22: 1796-1801. Go to original source... Go to PubMed...
    5. Casu A, Trucco M, Pietropaolo M. A look to the future: prediction, prevention and cure including islet cell trasplantation and stem cell therapy. Pediatr Clin N Am 2005; 1779-1804. Go to original source... Go to PubMed...
    6. DPT-1 Study Group. Effects of insulin in relatives of patients with T1DM. N Engl J Med 2002; 346: 1685-1691. Go to original source... Go to PubMed...
    7. EURODIAB ACE Study Group. Variantion and trends in incidence of childhood diabetes. Lancet 2000; 355: 873-876. Go to original source...
    8. Feutren G, Papoz L, Assan R et al. Cyclosporin increase the rate and lenght of remissions in insulin dependent diabets of recent onset. Results of a multicenter double blind trial. Lancet 1986; 2: 119-124. Go to original source... Go to PubMed...
    9. Foulis AK, McGill M, Faurquaharson MA. Insulitis in T1DM in man - macrophages, lymhopcytes and interfeton-gamma containing cells. J Pathol 1991; 165: 97-101. Go to original source... Go to PubMed...
    10. Gale EA, Bingley PJ, Emmet CL at al. ENDIT: a randomised controlled trial of intervention before onset of T1DM. Lancet 2004; 363: 25-31. Go to original source... Go to PubMed...
    11. Gillespie K. Type 1 diabetes: pathogenesis and prevention. CMAJ 2006; 175(2): 165-170. Go to original source... Go to PubMed...
    12. Keymeulen B, Vendemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset T1DM. N Eng J Med 2005; 352: 2598-2608. Go to original source... Go to PubMed...
    13. Nerup J, Platz P, Andersen OO et al. Lancet 1974; 2: 864-866.
    14. Ryan EA, Patty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069. Go to original source... Go to PubMed...
    15. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with T1DM using a glucocorticoid free imunosuppressive regimen. N Eng J Med 2000; 343: 230-238. Go to original source... Go to PubMed...
    16. Skyler JS. Prediction and prevention of type 1 diabetes: progress, problems and prospects. Clin Pharmacol Ther. 2007; 81(5): 768-771. Go to original source... Go to PubMed...
    17. Verge CF, Stenger D, Bonifacio E at al. Combined use of autoantibodies in T1DM. Combinatiorial Islet autoantibody workshop. Diabetes 1998; 47: 1857-1866. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.